GLP-1 receptor agonist and composition and use thereof
Provided are a GLP-1 receptor agonist compound and a composition and use thereof. The compound can be used for treating or preventing GLP-1 receptor-mediated diseases or disorders and related diseases or disorders.
1. A compound having a structure of Formula II-4:
or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein:
Y 1 is N;
m is 0;
R 4 is hydrogen;
R 1 is selected from halogen; and
R 0 is hydrogen.
2. The compound according to claim 1 , wherein R 1 is selected from F, and Cl.
3. The compound according to claim 1 , which is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
4. A pharmaceutical composition comprising the compound according to claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
5. A method for treating a GLP-1 receptor mediated or related disease or disorder in a subject, wherein said disease or disorder is selected from a group consisting of diabetes, hyperglycemia, insulin resistance, glucose intolerance, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, adipocyte dysfunction, obesity, dyslipidemia, and hyperinsulinemia comprising administering to the subject a therapeutically effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.
6. The compound according to claim 1 , which is:
or a pharmaceutically acceptable salt or stereoisomer thereof.
7. A pharmaceutical composition comprising the compound according to claim 2 , or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
8. A method for treating a GLP-1 receptor mediated or related disease or disorder in a subject, wherein said disease or disorder is selected from a group consisting of diabetes, hyperglycemia, insulin resistance, glucose intolerance, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, adipocyte dysfunction, obesity, dyslipidemia, and hyperinsulinemia, comprising administering to the subject a therapeutically effective amount of the compound according to claim 2 , or a pharmaceutically acceptable salt or stereoisomer thereof.
9. A pharmaceutical composition comprising the compound according to claim 3 , or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
10. A method for treating a GLP-1 receptor mediated or related disease or disorder in a subject, wherein said disease or disorder is selected from a group consisting of diabetes, hyperglycemia, insulin resistance, glucose intolerance, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, adipocyte dysfunction, obesity, dyslipidemia, and hyperinsulinemia, comprising administering to the subject a therapeutically effective amount of the compound according to claim 3 , or a pharmaceutically acceptable salt or stereoisomer thereof.
11. A pharmaceutical composition comprising the compound according to claim 6 , or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
12. A method for treating a GLP-1 receptor mediated or related disease or disorder in a subject, wherein said disease or disorder is selected from a group consisting of diabetes, hyperglycemia, insulin resistance, glucose intolerance, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, adipocyte dysfunction, obesity, dyslipidemia, and hyperinsulinemia, comprising administering to the subject a therapeutically effective amount of the compound according to claim 6 , or a pharmaceutically acceptable salt or stereoisomer thereof.